Overview of the cancer vaccine field

Kudrin, Alex; Hanna, Michael G.

doi:10.4161/hv.20474

Cited by 20 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since a cancer vaccine was licensed by the FDA for the first time in the United States [1], [2], [33], there has been greatly renewed interest in cancer vaccines and identifying useful tumor antigens [3]–[5]. Epitope enhancement by sequence modification was designed to improve such vaccines by increasing the immunogenicity of cancer epitopes that are often derived from self antigens [3], [6]–[8], [34], [35].…”

Section: Discussionmentioning

confidence: 99%

“…Immunotherapy may have great potential as a promising treatment for cancer patients because of its specificity and freedom from toxic effects of chemotherapies. Since sipuleucel-T became the first cancer vaccine licensed in the United States [1], [2], there has been greatly renewed interest in cancer vaccines [3]–[5]. Thus, novel tumor antigens specific to particular cancer types are of great interest.…”

Section: Introductionmentioning

confidence: 99%

“…Discovering tumor-specific antigens is critical to the development of effective cancer immunotherapy [5]. Recently, a novel tumor-associated antigen, POTE, was identified from a variety of human cancers [10], [11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE

et al. 2013

View full text Add to dashboard Cite

Identification of CD8+ T cell epitopes that can induce T cells to kill tumor cells is a fundamental step for development of a peptide cancer vaccine. POTE protein is a newly identified cancer antigen that was found to be expressed in a wide variety of human cancers, including prostate, colon, lung, breast, ovary and pancreas. Here, we determined HLA-A2.1-restricted cytotoxic T lymphocyte (CTL) epitopes in the POTE protein, and also designed enhanced epitopes by amino acid (AA) substitutions. Five 9-mer peptides were first selected and their binding affinity to HLA-A2 molecules was measured by the T2 binding assay. POTE 272–280 and POTE 323–331 showed the strongest HLA-A2 binding affinity. AA substituted peptides POTE 252-9V (with valine at position 9), POTE 553-1Y (with tyrosine at position 1) and POTE 323-3F (with phenylalanine at position 3) conferred higher affinity for HLA-A2, and induced CTL responses cross-reactive with wild type antigens. While POTE 252-9V was the strongest in this respect, POTE 323-3F had the greatest increase in immunogenicity compared to wild type. Importantly, two modified epitopes (POTE-553-1Y and POTE-323-3F) induced CTLs that killed NCI-H522, a POTE-expressing HLA-A2+ human non-small cell lung cancer cell line, indicating natural endogenous processing of these epitopes. In conclusion, the immunogenicity of POTE epitopes can be enhanced by peptide modification to induce T cells that kill human cancer cells. A combination of POTE 553-1Y and POTE 323-3F epitopes might be an attractive vaccine strategy for HLA-A2 cancer patients to overcome tolerance induced by tumors and prevent escape.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Robust immune responses are required for the eradication of malignant cells 1 , 2 . Circulating cancer cells are considered to be more susceptible to immune attacks as their likelihood to encounter immune cells is enhanced, and they are devoid of a protective (immunosuppressive) microenvironment 1 .…”

mentioning

confidence: 99%

A co-stimulatory trap set by myeloid leukemia cells

Esendağlı¹

2013

OncoImmunology

View full text Add to dashboard Cite

show abstract

“…These clinical trials have led to the possibility of developing new peptidebased cancer immunotherapies. However, these therapies have seen only a few recent successes and a tremendous number of failures [14]. In fact, clinical trials of TAA cell-targeted strategies are not always accepted because of the lack of reliable markers and the poor understanding of their behavior.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer

Miyata

Kumagai

Nagaoka

et al. 2015

CBM

View full text Add to dashboard Cite

Abstract. BACKGROUND: Colorectal cancer (CRC) is one of the most commonly diagnosed cancers, and novel effective treatments and diagnostic tools are urgently required. OBJECTIVE: The selection of appropriate targeting tumor-associated antigens (TAAs) is critical for immunotherapy. Therefore, we analyzed TAA expression levels and investigated their relationship with clinical factors in adjacent normal mucosa (ANM) and CRC tissue. METHODS: We obtained specimens of CRC primary tumors and matched ANM from 137 patients with CRC who underwent surgical resection. The mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed. RESULTS: The expression levels of all seven TAAs were significantly higher in CRC tissues than in ANM. Expression levels of WT1 in CRC tissues did not correlate with the cell cycle. Furthermore, WT1 expression in CRC tissues was significantly related to tumor progression, lymph node metastasis, distant metastasis and clinical stage. CONCLUSIONS: WT1 is a potential marker for prognosis and tumor progression in CRC.

show abstract

Overview of the cancer vaccine field

Cited by 20 publications

References 5 publications

Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE

Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE

A co-stimulatory trap set by myeloid leukemia cells

Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer

Contact Info

Product

Resources

About